Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN).

Full DD Report for DFFN

You must become a subscriber to view this report.


Recent News from (NASDAQ: DFFN)

Diffusion Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
CHARLOTTESVILLE, Va., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molec...
Source: GlobeNewswire
Date: August, 29 2018 08:00
Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Enrollment continues in Phase 3 GBM brain cancer trial Key European patent validated covering oral formulation of TSC Preparing for Phase 2 stroke trial with in-ambulance administration of TSC CHARLOTTESVILLE, Va., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc...
Source: GlobeNewswire
Date: August, 13 2018 08:30
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for...
Source: SeekingAlpha
Date: June, 16 2018 09:00
Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC
CHARLOTTESVILLE, Va., June 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced the validati...
Source: GlobeNewswire
Date: June, 12 2018 08:30
CORRECTION: Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
In the release issued under the same headline on May 10, 2018 by Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN), please note that in the Consolidated Balance Sheets table, Cash and cash equivalents row, under March 31, 2018, the figure should read $16,199,481 rather than $6,199...
Source: GlobeNewswire
Date: May, 29 2018 13:04
Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Patient screening and enrollment are underway in Phase 3 inoperable GBM brain cancer trial Key U.S. Patent Issued Clinical trial preparations are ongoing for Phase 2 trial with TSC in stroke CHARLOTTESVILLE, Va., May 10, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. ...
Source: GlobeNewswire
Date: May, 10 2018 16:05
Diffusion Pharmaceuticals to Present at The MicroCap Conference
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (''Diffusion'' or ''the Company''), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced that management will present an overview of the Co...
Source: ACCESSWIRE
Date: April, 03 2018 16:00
Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update
Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway Raised $12 Million in Underwritten Public Offering Preparing to Commence Clinical Trial with TSC in Stroke Expanded Intellectual Property Portfolio with New Key Patents CHARLOTTESVILLE, Va., April 03, ...
Source: GlobeNewswire
Date: April, 03 2018 07:30
Diffusion Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference
CHARLOTTESVILLE, Va., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced that David K...
Source: GlobeNewswire
Date: February, 06 2018 16:00
Diffusion Pharma awarded two U.S. patents covering lead candidate TSC; shares up 10%
Diffusion Pharmaceuticals ( DFFN +9.9% ) receives Notices of Allowance from the USPTO regarding two patent applications covering method of use and composition of matter for lead drug trans sodium crocetinate (TSC). More news on: Diffusion Pharmaceuticals Inc., Healthcare stocks news, S...
Source: SeekingAlpha
Date: February, 01 2018 09:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-080.3840.3950.3970.3795,514
2018-05-180.46730.45010.480.4501134,839
2018-05-170.46730.45010.480.4501134,839

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1017,438136,77912.7490Cover
2018-12-072,63811,90022.1681Cover
2018-12-069,41914,92963.0920Short
2018-12-04100,770312,19532.2779Cover
2018-12-034,8509,89649.0097Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DFFN.


About Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)

Logo for Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)

Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments including radiation therapy and chemotherapy. Diffusion is developing its lead drug, trans sodium crocetinate TSC , for use in the many cancer types in which tumor hypoxia oxygen deprivation is known to diminish the effectiveness of current treatments. TSC targets the cancer s hypoxic micro environment, re oxygenating treatment resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects. TSC has potential application in other indications involving hypoxia, such as stroke and neurodegenerative diseases. A Phase II clinical program, completed in the second quarter of , evaluated patients with newly diagnosed glioblastoma multiforme GBM . The study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care. This trial has been the basis for discussions with the U.S. Food and Drug Administration. A Phase III program in newly diagnosed GBM is being planned. Additional planned studies include a Phase II/III trial in pancreatic cancer. TSC s novel mechanism safely re oxygenates a range of tumor types, so its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve current standard of care treatments of many life threatening cancers.

 

 

 

Current Management

  • David G. Kalergis / CEO
  • Ben L. Shealy / Senior VP, Treasurer
  • David R. Jones, M.D. / Chief Med. Officer
  • John L. Gainer, Ph.D / Chief Scientific Officer
  • Thomas E. Byrne / General Counsel
  • Stephanie Carrington / IR
  • David G. Kalergis / Chairman
  • Alan G. Levin / Chairman
  • Robert W. Adams / Chairman
  • Isaac Blech /
  • Mark T. Giles /
  • John L. Gainer, Ph.D /

Current Share Structure

  • Market Cap: $9,584,342 - 03/09/2018
  • Authorized: 1,000,000,000 - 08/16/2016
  • Issue and Outstanding: 14,521,730 - 11/10/2017

 


Recent Filings from (NASDAQ: DFFN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 20 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 20 2018

 

 


Daily Technical Chart for (NASDAQ: DFFN)

Daily Technical Chart for (NASDAQ: DFFN)


Stay tuned for daily updates and more on (NASDAQ: DFFN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DFFN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DFFN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DFFN and does not buy, sell, or trade any shares of DFFN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/